Finally a response from the SEC to my and another
Post# of 36568
(Total Views: 543)
Posted On: 09/30/2021 12:50:05 PM
Finally a response from the SEC to my and another investors letter. The fact it took a while indicates to me some milestone has passed and he felt comfortable responding. Could be he just got around to answering. The second part of the bottom paragraph is boilerplate language he has used before.
Dear Messers. xxxxxxxx xxxxx:
Thank you for your emails about the status of Form S-1 filings by Generex Biotechnology Corporation (OTCMKTS: GNBT) subsidiary NuGenerex Immuno-Oncology, Inc. (OTCMKTS: NUGX).
You expressed concern about our reference in an email to Mr. Johnson to a particular SEC staff comment letter. Our purpose in mentioning the letter was solely to illustrate that the SEC posts letters from SEC staff reviewing company filings so that investors have access to the information in the letters. A review of the list of NUGX’s recent filings shows that the company last filed a Form S-1/A on May 20, 2021. We have no comment on the status of SEC staff review of NUGX’s Form S-1 filings.
You also underscored the importance to NUGX of having SEC review of its Form S-1 and amendments conclude so that NUGX can proceed with its planned IPO. The SEC’s Office of Investor Education and Advocacy processes many comments from individual investors and others. We keep records of the correspondence we receive in a searchable database that SEC staff may make use of in inspections, examinations, and investigations. In addition, some of the correspondence we receive is referred to other SEC offices and divisions for their review. If they have any questions or wish to respond directly to your comments, they will contact you.
Thank you again for contacting us.
Sincerely,
Steven Johnston
Special Counsel
Office of Investor Education and Advocacy
U.S. Securities and Exchange Commission
www.sec.gov
www.investor.gov
www.twitter.com/SEC_Investor_Ed
Dear Messers. xxxxxxxx xxxxx:
Thank you for your emails about the status of Form S-1 filings by Generex Biotechnology Corporation (OTCMKTS: GNBT) subsidiary NuGenerex Immuno-Oncology, Inc. (OTCMKTS: NUGX).
You expressed concern about our reference in an email to Mr. Johnson to a particular SEC staff comment letter. Our purpose in mentioning the letter was solely to illustrate that the SEC posts letters from SEC staff reviewing company filings so that investors have access to the information in the letters. A review of the list of NUGX’s recent filings shows that the company last filed a Form S-1/A on May 20, 2021. We have no comment on the status of SEC staff review of NUGX’s Form S-1 filings.
You also underscored the importance to NUGX of having SEC review of its Form S-1 and amendments conclude so that NUGX can proceed with its planned IPO. The SEC’s Office of Investor Education and Advocacy processes many comments from individual investors and others. We keep records of the correspondence we receive in a searchable database that SEC staff may make use of in inspections, examinations, and investigations. In addition, some of the correspondence we receive is referred to other SEC offices and divisions for their review. If they have any questions or wish to respond directly to your comments, they will contact you.
Thank you again for contacting us.
Sincerely,
Steven Johnston
Special Counsel
Office of Investor Education and Advocacy
U.S. Securities and Exchange Commission
www.sec.gov
www.investor.gov
www.twitter.com/SEC_Investor_Ed
(0)
(0)